Galapagos NV

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1 studies, pre-clinical studies and discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people’s lives. Galapagos’ aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need. The Galapagos group, including fee-for-service subsidiairy Fidelta, has more than 1,000 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Germany, Italy, Spain, Switzerland, the US, UK, and Croatia.

As a biotechnology company, our focus lies in policy files and initiatives related to the healthcare sector, for instance the European Commission’s ongoing pharmaceuticals consultation, as well as any file that has an impact on intellectual property, data protection, research funding, corporate governance, taxation, investment, competition, innovation in healthcare, market access, pricing of medicines, patient access.

2

0.5

No lobbyists with EP accreditations

No

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

II - In-house lobbyists and trade/business/professional associations

Companies & groups